Navigation Links
New mouse model confirms how type 2 diabetes develops
Date:5/3/2013

Researchers at Lund University in Sweden have developed a new mouse model that answers the question of what actually happens in the body when type 2 diabetes develops and how the body responds to drug treatment. Long-term studies of the middle-aged mouse model will be better than previous studies at confirming how drugs for type 2 diabetes function in humans.

"The animal models for type 2 diabetes studies that have previously existed have not been optimal because they use young mice. Our idea was to create a model that resembles the situation in the development of type 2 diabetes in humans. We generally get the disease in middle age when we start to put on weight and live a more sedentary, and more stressful, life. Our new middle-aged mouse model has enabled us to study long-term physiological effects of the development and treatment of type 2 diabetes in a completely new way", said Bilal Omar, one of the researchers behind the study.

What the Lund researchers have done is to feed normal mice fatty food over a long period from the age of eight months, i.e. middle age, until the end of their natural lives at the age of two. The mice become overweight, and develop high blood sugar levels and reduced insulin release, as expected before the onset of type 2 diabetes.

"Throughout the period we were able to study the process that leads to the development of type 2 diabetes with a lifestyle like that of people predisposed to the condition", said Bilal Omar.

In the study, the researchers could confirm that fatty foods lead to inflammation in the islets of Langerhans in the pancreas, which produce insulin. Researchers have seen inflammation in the islets in people with type 2 diabetes, but in Bilal Omar's view, it is only with the new mouse model that it can really be confirmed. Inflammation in these islets is an important risk factor for type 2 diabetes.

"What was so interesting and exciting was that the mice that were treated with DPP-4 inhibitors, a class of drugs used for type 2 diabetes, did not develop inflammation and they maintained good insulin production. They were still obese, but had normal blood sugar, were otherwise healthy and lived longer", said Bilal Omar.

Researchers have worked for decades and on many fronts to understand the causes and course of diabetes. Models of different diseases are therefore an important tool for the development of new and better drugs, and a requirement to develop the best possible drugs is to understand what is happening on a physiological level.

"The goal is to design drugs and treatments which, if they can't cure the disease, can at least give the patient a better quality of life for several years", said Bilal Omar.

"Another aspect of our findings is that the inflammation in the islets was caused by a high-fat diet. Even if it is too early to draw parallels with the diet of humans, it makes it doubtful whether a high-fat diet over a long period should be recommended, as in the LCHF diet", said Professor Bo Ahrn, another of the researchers behind the study.


'/>"/>

Contact: Bilal Omar
46-462-220-760
Lund University
Source:Eurekalert

Related medicine news :

1. Transparent Mouse Brain Could Shed Light on Human Brain Health
2. Bitter melon juice prevents pancreatic cancer in mouse models
3. Mouse model improves understanding of clear cell sarcoma
4. Mouse menopause model sheds light on UTIs in post-menopausal women
5. Mouse Study Offers Clues to Obesity-Diabetes Link
6. Bright Light at Night Could Up Depression Risk, Mouse Study Suggests
7. New, improved mouse model of human Alzheimers may enable drug discovery
8. Mouse model exposes a new type of T cell to target melanoma
9. A CNIO team creates a unique mouse model for the study of aplastic anaemia
10. Mouse With Human-Like Immune System Could Advance AIDS Research
11. Scientists develop mouse model that could lead to new therapies for liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology: